Table 1.

Patient characteristics, immunosuppressive regimen, immunologic data, and details of vaccine administration

Patient no.	Age, yr	Sex	Ethnicity	Disease phenotype	ANCA type and titer at the time of booster, U/ml	eGFR at the time of booster, ml/min per 1.73 m2	Proteinuria at the time of booster, mg	Induction IS	Maintenance IS	Cumulative RTX dose, g	Interval between last RTX and first vaccine dose, mo	CD19 count, cells/ml (%)	Time point of CD19 measurement	Vaccine types	SARS-CoV-2 spike protein IgG titer (immunoassay), AU
1	67	Male	White	GPA	PR3 (30.8)	68	91	RTX + steroids	RTX	8.2	4	<20 (0)	2 wk before second vaccine dose	JNJ and then Pfizer–BioNTech series	>12
2	80	Female	White	MPA	MPO (<9)	34	307	RTX + steroids	RTX	9	5	<20 (0)	1 wk before second vaccine dose	JNJ and then Moderna series	<12 (DiaSorin Liaison)
3	70	Female	White	MPA	MPO (NA)	44	219	Cyclophosphamide + steroids	RTX	3	3	<20 (0)	1 mo after second vaccine dose	Pfizer–BioNTech and then JNJ	<1 (Roche Elecysys)

ANCA, anti–neutrophil cytoplasmic antibody; AU, arbitrary unit; eGFR, estimated glomerular filtration rate; GPA, granulomatosis with polyangiitis; ID, identifier; IS, immunosuppression; JNJ, Johnson & Johnson; MPA, microscopic polyangiitis; MPO, myeloperoxidase; NA, not available; PR3, proteinase 3; RTX, rituximab; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.